Physician profile
Ashok Jain
NPI 1629091277
$2,443.47
in general payments reported to CMS, 2019-2025
24 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $305 · 2021: $340 · 2022: $444 · 2023: $411 · 2024: $351 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $700.38 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $269.83 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $268.62 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $179.39 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $154.49 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.31 | 2019-2022 | |
| Abbott Laboratories | $121.32 | 2022-2024 | Proclaim, Freestyle Libre 2 |
| Astellas Pharma US INC | $87.02 | 2019-2021 | |
| Lilly USA, LLC | $71.54 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $66.57 | 2024 | Voquezna |
| Abbvie INC. | $48.66 | 2023 | |
| Biosense Webster, INC. | $47.62 | 2023 | Carto 3 |
| Cumberland Pharmaceuticals, INC. | $46.85 | 2020-2021 | |
| Dexcom, INC. | $42.30 | 2021-2022 | |
| Biofire Diagnostics, LLC | $39.43 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $36.90 | 2024 | Eliquis |
| Verona Pharma, INC. | $21.92 | 2025 | Ohtuvayre |
| Exact Sciences Corporation | $20.87 | 2025 | The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $19.20 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.72 | 2019 | |
| Edwards Lifesciences Corporation | $15.65 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $15.55 | 2023 | Crysvita |
| Shire North American Group INC | $15.19 | 2019 | |
| Genentech USA, INC. | $14.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.